Apellis Pharmaceuticals Inc [APLS] stock prices are down -2.30% to $36.16 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APLS shares have gain 6.70% over the last week, with a monthly amount drifted -8.53%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on May 31, 2024, when Piper Sandler initiated its Neutral rating and assigned the stock a price target of $46. Previously, Jefferies upgraded its rating to Buy on February 05, 2024, and elevated its price target to $80. On December 14, 2023, downgrade downgraded it’s rating to Equal Weight. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $74 on November 09, 2023. Mizuho initiated its recommendation with a Neutral and recommended $42 as its price target on November 02, 2023. JP Morgan upgraded its rating to Overweight for this stock on October 06, 2023, and upped its price target to $81. In a note dated September 15, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $34 to $64.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $23.86 and $73.80 over the past year. Currently, Wall Street analysts expect the stock to reach $75.81 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $36.16 at the most recent close of the market. An investor can expect a potential return of 109.65% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 628.79M for trailing twelve months, representing a surge of 110.26%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -1.39 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.19 points at the first support level, and at 34.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.02, and for the 2nd resistance point, it is at 37.87.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 5.08. As well, the Quick Ratio is 4.18, while the Cash Ratio is 2.14. Considering the valuation of this stock, the price to sales ratio is 7.00, the price to book ratio is 16.65.
Transactions by insiders
Recent insider trading involved Dunlop A. Sinclair, Director, that happened on Jun 21 ’24 when 37000.0 shares were sold. Chief Scientific Officer, Deschatelets Pascal completed a deal on May 08 ’24 to sell 78907.0 shares. Meanwhile, Chief Scientific Officer Deschatelets Pascal sold 69107.0 shares on Apr 08 ’24.
